Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
650 stopped studies mapped to Myeloid Leukemia and descendants · 88% state a reason
Over the 650 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03515707 | Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal… | Phase 2 | withdrawn | May 3, 2018 | Fred Hutchinson Cancer Center | PI recommended closure | Other (stated, no rule matched) |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | Phase 2 | terminated | Feb 14, 2008 | Abramson Cancer Center at Penn Medicine | Study terminated. Eisai's Targretin acquired by another pharmaceutical company. | Sponsor / business decision |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell… | Phase 2 | terminated | Oct 17, 2018 | Milton S. Hershey Medical Center | Funding pulled | Funding |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02782403 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase… | Phase 1 | terminated | May 25, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to… | Enrollment / accrual |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or… | Phase 1 / Phase 2 | withdrawn | Jul 30, 2020 | M.D. Anderson Cancer Center | The original sponsor was acquired by a new company and has elected to end funding for all… | Investigator |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | Phase 1 / Phase 2 | terminated | Aug 2, 2012 | PrECOG, LLC. | Study stopped per Novartis request due to futility from another study. | Efficacy / futility |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | M.D. Anderson Cancer Center | PDOL request | Other (stated, no rule matched) |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation… | Phase 1 | withdrawn | Oct 16, 2019 | Sherif Farag | Funder withdrew funding after not accruing any subjects after 1 year. | Enrollment / accrual |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects… | Phase 2 | withdrawn | Feb 23, 2017 | Immune System Key Ltd | No recruitment since initiation | Enrollment / accrual |
| NCT04106076 | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | Phase 1 | withdrawn | Sep 26, 2019 | Cellectis S.A. | The trial was discontinued due to sponsor's decision and not a consequence of any safety concern | Safety / toxicity |
| NCT03152526 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK)… | N/A | terminated | May 15, 2017 | Miltenyi Biotec B.V. & Co. KG | Slow enrollment | Enrollment / accrual |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic… | Phase 1 / Phase 2 | withdrawn | Jul 10, 2019 | Vanderbilt-Ingram Cancer Center | Loss of funding | Funding |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | Phase 2 | terminated | Oct 24, 2018 | NYU Langone Health | Safety concerns | Safety / toxicity |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2016 | Bio-Path Holdings, Inc. | No enrollment | Enrollment / accrual |
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or… | Phase 2 | terminated | Mar 6, 2017 | St. Jude Children's Research Hospital | Due to slow enrollment | Enrollment / accrual |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone… | Phase 1 / Phase 2 | terminated | Jan 16, 2014 | Albert Einstein College of Medicine | Low accrual | Enrollment / accrual |
| NCT02906696 | Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After… | Phase 2 | terminated | Sep 20, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request due to competing priorities. | Other (stated, no rule matched) |
| NCT01636609 | Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute… | Phase 1 | terminated | Jul 10, 2012 | M.D. Anderson Cancer Center | In 2013 the FDA put a temporary hold on the trial and the Phase II portion of this study was… | Other (stated, no rule matched) |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory…(CyFi2) | Phase 2 | withdrawn | Sep 24, 2019 | AVEO Pharmaceuticals, Inc. | Urgent shift among clinical sites toward efforts to combat COVID-19 pandemic;impacted feasibility… | COVID-19 / pandemic |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy…(UFT RT Phase 3) | Phase 3 | terminated | Sep 21, 2005 | Institut Cancerologie de l'Ouest | Terminated after interim analysis | Efficacy / futility |
| NCT02109627 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | Phase 1 | terminated | Apr 10, 2014 | C. Babis Andreadis | Low Accrual | Enrollment / accrual |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | Phase 2 | terminated | Jan 28, 2015 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese…(Japanese AML) | Phase 1 | terminated | May 1, 2017 | Gilead Sciences | No signal of efficacy with Entospletinib | Efficacy / futility |
| NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | Phase 1 | terminated | Aug 23, 2016 | Polaris Group | Study Termination | Other (stated, no rule matched) |
| NCT02341495 | Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML…(EXJADE) | Phase 2 | terminated | Jan 19, 2015 | Elizabeth Henry | Study was terminated early due to low patient accrual. | Enrollment / accrual |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid… | Phase 1 | terminated | Oct 27, 2015 | ADC Therapeutics S.A. | Slow enrollment | Enrollment / accrual |
| NCT00939653 | T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia… | Phase 2 | terminated | Jul 15, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Due to insufficient research institution participation and patient enrollment | Enrollment / accrual |
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | Phase 1 / Phase 2 | terminated | Oct 4, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The manufacturer discontinued necessary reagents. | Drug supply |
| NCT02370888 | Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia…(UF-BMT-MRD-101) | Phase 1 | terminated | Feb 25, 2015 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT02226497 | Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic… | N/A | terminated | Aug 27, 2014 | Fred Hutchinson Cancer Center | Insufficient staff | Other (stated, no rule matched) |
| NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With… | N/A | terminated | May 22, 2014 | Masonic Cancer Center, University of Minnesota | Replaced by another study. | Other (stated, no rule matched) |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT02174445 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of…(DECLINE) | Phase 3 | terminated | Jun 25, 2014 | Prof. Dr. Nikolas von Bubnoff | very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements | Enrollment / accrual |
| NCT02954653 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In… | Phase 1 | terminated | Nov 3, 2016 | Pfizer | The study was terminated due to a change in sponsor prioritization. | Other (stated, no rule matched) |
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Mar 30, 2018 | Hutchison Medipharma Limited | Slow Enrollment | Enrollment / accrual |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute…(ENTO in AML) | Phase 1 / Phase 2 | terminated | Jan 22, 2015 | Gilead Sciences | not stated | Not stated |
| NCT03126864 | Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to… | Phase 1 | terminated | Apr 24, 2017 | M.D. Anderson Cancer Center | Terminated per the PI's request. | Other (stated, no rule matched) |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | Phase 1 | withdrawn | Aug 2, 2018 | Celyad Oncology SA | Sponsor decision | Sponsor / business decision |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT00568633 | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | Phase 3 | terminated | Dec 6, 2007 | Stanford University | Poor accrual | Enrollment / accrual |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | Phase 2 | terminated | Jun 10, 2013 | Emory University | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 1, 2021source: clinicaltrials